Six States lead the Covid surge
March 11, 2021
Covaxin has already been administered to over 19 lakh people and has stood the test of safety - The Hindu
Covaxin has already been administered to over 19 lakh people and has stood the test of safety - The Hindu×
RELATED
At 23,000, new cases at highest in 2021; Maharashtra worst hit; Covaxin use rules eased
Even as India recorded the steepest increase in daily Covid-19 cases in 2021 in the last 24 hours, the drug regulator relaxed the conditions for use ofCovaxin, the indigenously-developed Covid-19 vaccine.
The number of new Covid-19 cases reported since Wednesday morning rose to 23,000, the highest since January 1. Six States, including Maharashtra and Kerala, accounted for 86 per cent of the new infections.
March 11, 2021
The total number of doses of Covaxin administered till February 9 was 3.03 lakh - PTI
The total number of doses of Covaxin administered till February 9 was 3.03 lakh - PTI×
DCGI panel seen scrapping ‘clinical trial mode’ condition for the Bharat Biotech vaccine, based on 81 per cent efficacy report The acceptance for Covaxin, the Covid-19 vaccine developed entirely by the Hyderabad-based Bharat Biotech, appears to be rising perhaps after Prime Minister Narendra Modi took it, on March 1.
Even as an official source confirmed to
BusinessLine on Tuesday that the Health Ministry has ordered for 45 lakh doses of Covaxin for delivery by March 16, in another significant development, an independent Subject Expert Committee of the Drugs Controller General of India (DCGI) is learnt to have recommended ending the “clinical trial mode” condition for the vaccine, based on interim clinical trials results which showed 81 per cent efficacy. A final decision
Covaxin Shots May Be Given Without Consent Form, Expert Panel Recommends Covaxin Shots May Be Given Without Consent Form, Expert Panel Recommends The subject expert committee recommended Covaxin to be given emergency use authorisation after going through the Indian vaccine s phase 3 trial data
COVID-19 vaccination: Bharat Biotech is the manufacturer of Covaxin
New Delhi:
Bharat Biotech s COVID-19 vaccine Covaxin can be taken off clinical trial mode, a subject expert committee that has been monitoring the vaccine development has recommended to the country s drugs regulator DCGI, which will take a final call on the matter.
If Covaxin is no longer administered under clinical trial mode, people don t have to sign a consent form to take the vaccine.
The drug regulators subject expert committee (SEC) will meet on Thursday to consider the vaccine makers request and review the data. “The company has approached the regulator so that the mandated clinical mode be reviewed and removed,” said a senior government official.
India News: An expert panel of India's central drugs authority on Wednesday recommended granting emergency use authorisation to Bharat Biotech's indigenously deve